Kardigan (NASDAQ:KARD) Cut to Sell at Wall Street Zen

Posted by Brian Himes on Aug 18th, 2026

Wall Street Zen lowered shares of Kardigan (NASDAQ:KARD – Free Report) from a hold rating to a sell rating in a research note published on Saturday.

Several other equities research analysts also recently commented on KARD. Leerink Partners initiated coverage on Kardigan in a report on Monday, July 13th. They issued an “outperform” rating and a $37.00 price objective for the company. TD Cowen started coverage on shares of Kardigan in a report on Monday, July 13th. They set a “buy” rating and a $46.00 target price on the stock. JPMorgan Chase & Co. assumed coverage on shares of Kardigan in a research report on Monday, July 13th. They set an “overweight” rating and a $51.00 price target on the stock. Jefferies Financial Group began coverage on shares of Kardigan in a research note on Monday, July 13th. They issued a “buy” rating and a $40.00 price target for the company. Finally, Zacks Research raised shares of Kardigan to a “hold” rating in a research report on Wednesday, July 15th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.50.

Check Out Our Latest Report on KARD

Kardigan Stock Performance

NASDAQ:KARD opened at $20.55 on Friday. Kardigan has a 52-week low of $16.25 and a 52-week high of $27.00. The firm has a 50-day moving average of $22.10.

Kardigan (NASDAQ:KARD – Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($4.61) EPS for the quarter. On average, analysts anticipate that Kardigan will post -3.18 earnings per share for the current year.

Insider Activity at Kardigan

In other news, Director Paul L. Berns purchased 1,250,000 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was acquired at an average cost of $16.00 per share, with a total value of $20,000,000.00. Following the acquisition, the director owned 15,042,035 shares in the company, valued at approximately $240,672,560. This trade represents a 9.06% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Arch Venture Partners Xiii, Ll purchased 1,250,000 shares of Kardigan stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $16.00 per share, with a total value of $20,000,000.00. Following the completion of the purchase, the director directly owned 15,042,035 shares in the company, valued at $240,672,560. This trade represents a 9.06% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Institutional Investors Weigh In On Kardigan

A number of institutional investors have recently modified their holdings of the business. Legal & General Group Plc acquired a new position in shares of Kardigan in the second quarter valued at about $119,000. Bank of America Corp DE acquired a new stake in Kardigan in the 2nd quarter worth about $1,283,000. Bank of New York Mellon Corp acquired a new stake in Kardigan in the 2nd quarter worth about $9,010,000. Finally, Jupiter Topco LLC bought a new stake in Kardigan in the 2nd quarter valued at about $17,715,000.

About Kardigan

(Get Free Report)

Kardigan Inc is a clinical-stage precision therapeutics company developing medicines which target the root cause of specific cardiovascular diseases. Kardigan Inc is based in South San Francisco, California.